BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 16081691)

  • 1. Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules.
    Palena C; Foon KA; Panicali D; Yafal AG; Chinsangaram J; Hodge JW; Schlom J; Tsang KY
    Blood; 2005 Nov; 106(10):3515-23. PubMed ID: 16081691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of MVA-CD40L and MVA-TRICOM vectors for enhancing the immunogenicity of chronic lymphocytic leukemia (CLL) cells.
    Litzinger MT; Foon KA; Tsang KY; Schlom J; Palena C
    Leuk Res; 2010 Oct; 34(10):1351-7. PubMed ID: 20122733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients.
    Litzinger MT; Foon KA; Sabzevari H; Tsang KY; Schlom J; Palena C
    Cancer Immunol Immunother; 2009 Jun; 58(6):955-65. PubMed ID: 19009294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules.
    Briones J; Timmerman JM; Panicalli DL; Levy R
    J Natl Cancer Inst; 2003 Apr; 95(7):548-55. PubMed ID: 12671023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.
    Tsang KY; Palena C; Yokokawa J; Arlen PM; Gulley JL; Mazzara GP; Gritz L; Yafal AG; Ogueta S; Greenhalgh P; Manson K; Panicali D; Schlom J
    Clin Cancer Res; 2005 Feb; 11(4):1597-607. PubMed ID: 15746065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells.
    Buhmann R; Nolte A; Westhaus D; Emmerich B; Hallek M
    Blood; 1999 Mar; 93(6):1992-2002. PubMed ID: 10068672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
    Hodge JW; Poole DJ; Aarts WM; Gómez Yafal A; Gritz L; Schlom J
    Cancer Res; 2003 Nov; 63(22):7942-9. PubMed ID: 14633725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules.
    Hodge JW; Rad AN; Grosenbach DW; Sabzevari H; Yafal AG; Gritz L; Schlom J
    J Natl Cancer Inst; 2000 Aug; 92(15):1228-39. PubMed ID: 10922408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of herpes simplex virus-1 amplicon-based immunotherapy for chronic lymphocytic leukemia.
    Tolba KA; Bowers WJ; Hilchey SP; Halterman MW; Howard DF; Giuliano RE; Federoff HJ; Rosenblatt JD
    Blood; 2001 Jul; 98(2):287-95. PubMed ID: 11435295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced activation of rhesus T cells by vectors encoding a triad of costimulatory molecules (B7-1, ICAM-1, LFA-3).
    Shankar P; Schlom J; Hodge JW
    Vaccine; 2001 Dec; 20(5-6):744-55. PubMed ID: 11738738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules.
    Hodge JW; Grosenbach DW; Rad AN; Giuliano M; Sabzevari H; Schlom J
    Vaccine; 2001 May; 19(25-26):3552-67. PubMed ID: 11348723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen.
    Hodge JW; Higgins J; Schlom J
    Vaccine; 2009 Jul; 27(33):4475-82. PubMed ID: 19450631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells.
    Zhu M; Terasawa H; Gulley J; Panicali D; Arlen P; Schlom J; Tsang KY
    Cancer Res; 2001 May; 61(9):3725-34. PubMed ID: 11325845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury.
    Heery CR; Palena C; McMahon S; Donahue RN; Lepone LM; Grenga I; Dirmeier U; Cordes L; Marté J; Dahut W; Singh H; Madan RA; Fernando RI; Hamilton DH; Schlom J; Gulley JL
    Clin Cancer Res; 2017 Nov; 23(22):6833-6845. PubMed ID: 28855356
    [No Abstract]   [Full Text] [Related]  

  • 16. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes.
    Takahashi S; Rousseau RF; Yotnda P; Mei Z; Dotti G; Rill D; Hurwitz R; Marini F; Andreeff M; Brenner MK
    Hum Gene Ther; 2001 Apr; 12(6):659-70. PubMed ID: 11426465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A triad of costimulatory molecules synergize to amplify T-cell activation in both vector-based and vector-infected dendritic cell vaccines.
    Schlom J; Sabzevari H; Grosenbach DW; Hodge JW
    Artif Cells Blood Substit Immobil Biotechnol; 2003 May; 31(2):193-228. PubMed ID: 12751840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of IL-2R beta-binding cytokines on costimulatory properties of chronic lymphocytic leukaemia cells: implications for immunotherapy.
    Spaner DE; Hammond C; Mena J; Shi Y
    Br J Haematol; 2004 Dec; 127(5):531-42. PubMed ID: 15566356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HSV amplicon-mediated delivery of LIGHT enhances the antigen-presenting capacity of chronic lymphocytic leukemia.
    Tolba KA; Bowers WJ; Eling DJ; Casey AE; Kipps TJ; Federoff HJ; Rosenblatt JD
    Mol Ther; 2002 Oct; 6(4):455-63. PubMed ID: 12377186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes.
    Biagi E; Dotti G; Yvon E; Lee E; Pule M; Vigouroux S; Gottschalk S; Popat U; Rousseau R; Brenner M
    Blood; 2005 Mar; 105(6):2436-42. PubMed ID: 15536147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.